Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 368

Results For "C"

9223 News Found

Lupin receives tentative approval from USFDA for Selexipag for injection
Drug Approval | November 04, 2023

Lupin receives tentative approval from USFDA for Selexipag for injection

This product will be manufactured at Lupin's Nagpur facility in India


Tatva Chintan Pharma Chem reports Q2 FY24 consolidated PAT at Rs. 7.78 Cr
News | November 04, 2023

Tatva Chintan Pharma Chem reports Q2 FY24 consolidated PAT at Rs. 7.78 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 97.42 crores during the period ended September 30, 2023


The Prostate Cancer Foundation and Bayer announce Bayer – PCF Darolutamide Challenge Awards
News | November 03, 2023

The Prostate Cancer Foundation and Bayer announce Bayer – PCF Darolutamide Challenge Awards

In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer


Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI
Digitisation | November 03, 2023

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI

This project will aim to develop a next-generation A3 adenosine receptor drug agonists


Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr
News | November 03, 2023

Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr

Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023


Dabur India posts Q2 FY24 consolidated PAT at Rs. 515.05 Cr
News | November 03, 2023

Dabur India posts Q2 FY24 consolidated PAT at Rs. 515.05 Cr

The company has posted net profit of Rs.978.93 crores for the 6 months period ended September 30, 2023


Lincoln Pharmaceuticals posts Q2 FY24 consolidated PAT at Rs. 27.65 Cr
News | November 03, 2023

Lincoln Pharmaceuticals posts Q2 FY24 consolidated PAT at Rs. 27.65 Cr

Lincoln Pharmaceuticals has reported total income of Rs. 164.68 crores during the period ended September 30, 2023


Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr
News | November 03, 2023

Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr

Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023


Jubilant Ingrevia posts Q2 FY24 consolidated PAT at Rs. 57.49 Cr
News | November 02, 2023

Jubilant Ingrevia posts Q2 FY24 consolidated PAT at Rs. 57.49 Cr

The company has posted net profit of Rs.115.08 crores for half year ended September 30, 202


Zydus acquires UK based LiqMeds Group
News | November 02, 2023

Zydus acquires UK based LiqMeds Group

Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026